111 related articles for article (PubMed ID: 30828792)
1. Authors' reply to: Absence of the MAP2K5 germline variants c.G961A and c.T1100C in a wide series of familial non-medullary thyroid carcinoma Italian families. International Journal of Cancer 2019; in press.
Ye F; Gao H; Xiao L; Ding H; Huang Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Jul; 145(2):601-602. PubMed ID: 30828792
[No Abstract] [Full Text] [Related]
2. Absence of the MAP2K5 germline variants c.G961A and c.T1100C in a wide series of familial nonmedullary thyroid carcinoma Italian families.
Cirello V; Colombo C; Persani L; Fugazzola L
Int J Cancer; 2019 Jul; 145(2):600. PubMed ID: 30828786
[No Abstract] [Full Text] [Related]
3. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
4. Absence of germline mutations in genes within the MAP kinase pathway in familial non-medullary thyroid cancer.
Hou P; Xing M
Cell Cycle; 2006 Sep; 5(17):2036-9. PubMed ID: 16931913
[No Abstract] [Full Text] [Related]
5. HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series.
Cantara S; Marzocchi C; Castagna MG; Pacini F
J Endocrinol Invest; 2017 May; 40(5):557-560. PubMed ID: 27873212
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
7. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients.
Niccoli-Sire P; Murat A; Rohmer V; Franc S; Chabrier G; Baldet L; Maes B; Savagner F; Giraud S; Bezieau S; Kottler ML; Morange S; Conte-Devolx B;
J Clin Endocrinol Metab; 2001 Aug; 86(8):3746-53. PubMed ID: 11502806
[TBL] [Abstract][Full Text] [Related]
8. Reply to the Letter to the Editor 'Germline-somatic fluidity in guiding patient care. Reply to the Letter to the Editor "Choice of control tissue impacts designation of germline variants in a cohort of papillary thyroid carcinoma patients" by J. C. Rubinstein et al.' by E. Hahn & G. S. Charames.
Christison-Lagay ER; Rubinstein JC
Ann Oncol; 2020 Aug; 31(8):1090-1091. PubMed ID: 32428551
[No Abstract] [Full Text] [Related]
9. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.
Fugazzola L; Cerutti N; Mannavola D; Ghilardi G; Alberti L; Romoli R; Beck-Peccoz P
Clin Endocrinol (Oxf); 2002 Jan; 56(1):53-63. PubMed ID: 11849247
[TBL] [Abstract][Full Text] [Related]
10. Germline-sequence variants S836S and L769L in the RE arranged during Transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population.
Berard I; Kraimps JL; Savagner F; Murat A; Renaudin K; Nicolli-Sire P; Bertrand G; Moisan JP; Bezieau S
Clin Genet; 2004 Feb; 65(2):150-2. PubMed ID: 14984475
[No Abstract] [Full Text] [Related]
11. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
[TBL] [Abstract][Full Text] [Related]
12. RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series.
Fugazzola L; Muzza M; Mian C; Cordella D; Barollo S; Alberti L; Cirello V; Dazzi D; Girelli ME; Opocher G; Beck-Peccoz P; Persani L
Clin Endocrinol (Oxf); 2008 Sep; 69(3):418-25. PubMed ID: 18284634
[TBL] [Abstract][Full Text] [Related]
13. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
[TBL] [Abstract][Full Text] [Related]
14. Thyroid cancer genetics: multiple endocrine neoplasia type 2, non-medullary familial thyroid cancer, and familial syndromes associated with thyroid cancer.
Richards ML
Surg Oncol Clin N Am; 2009 Jan; 18(1):39-52, viii. PubMed ID: 19056041
[TBL] [Abstract][Full Text] [Related]
15. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.
Silva AL; Carmo F; Moura MM; Domingues R; Espadinha C; Leite V; Cavaco B; Bugalho MJ
Endocrine; 2015 Jun; 49(2):366-72. PubMed ID: 25725622
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a DHPLC-based assay for rapid detection of RET germline mutations in Italian patients with medullary thyroid carcinoma.
Torrente I; Arturi F; D'Aloiso L; Colosimo A; De Luca A; Ferretti E; Russo D; Chiefari E; Scarpelli D; Bisceglia M; Dallapiccola B; Filetti S
J Endocrinol Invest; 2004 Feb; 27(2):111-6. PubMed ID: 15129804
[TBL] [Abstract][Full Text] [Related]
18. Letter regarding the article: "Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of "thyroid-checked" controls" by Kern et al.
Colombo C; Fugazzola L; Muzza M; Proverbio MC; Cirello V
Eur J Med Genet; 2018 Feb; 61(2):104-105. PubMed ID: 28779995
[TBL] [Abstract][Full Text] [Related]
19. Familial non-medullary thyroid carcinoma: an update.
Nosé V
Endocr Pathol; 2008; 19(4):226-40. PubMed ID: 18931957
[TBL] [Abstract][Full Text] [Related]
20. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
